[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361857-105":59,"doc-detail-361857-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","low-dose-statins-restore-innate-immune-response-in-breast-cancer-cells-via-suppression-of-mutant-p53-original-research-article","Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53 - Original Research Article","","Breast cancer recurrence and treatment toxicity create a need for safer, more effective therapies. This study tests whether low-dose statins suppress activation of mutant TP53 and thereby interfere with tumor immune evasion. Using breast cancer cell lines spanning different p53 statuses and multiple molecular and imaging techniques, the work assesses innate immune signaling pathways. In vivo results in BALB/c mice evaluate TBK1/IRF3 activation and CD8+ T-cell infiltration, supporting innate immune restoration.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/low-dose-statins-restore-innate-immune-response-in-breast-cancer-cells-via-suppression-of-mutant-p53-original-research-article/361857/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/low-dose-statins-restore-innate-immune-response-in-breast-cancer-cells-via-suppression-of-mutant-p53-original-research-article/361857.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in breast cancer therapy?","Question",{"text":112,"@type":113},"It targets high recurrence and side effects by exploring a safer therapeutic strategy linked to mutant TP53–driven immune evasion.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do the authors investigate the role of mutant p53 and low-dose statins?",{"text":117,"@type":113},"They use breast cancer cell lines with different p53 statuses and apply Western blot, transfection, qRT-PCR, co-immunoprecipitation, nuclear fractionation, and immunohistochemistry.",{"name":119,"@type":110,"acceptedAnswer":120},"What key immune-related findings support the study’s conclusion?",{"text":121,"@type":113},"Statin treatment promotes IRF3 nuclear translocation; in vivo it increases phosphorylated TBK1 and IRF3 and induces CD8+ T lymphocyte infiltration in tumors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361857,1790497066,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","TYPE Original Research PUBLISHED 02 May 2025  \nDOI 10.3389/fphar.2025.1492305  \nOPEN ACCESS  \nEDITED BY  \nDefang Li,  \nBinzhou Medical University, China  \nREVIEWED BY  \nLei Li,  \nUniversity of Otago, New Zealand Meng Liu,  \nXinjiang Medical University, China  \n*CORRESPONDENCE  \nWenzhe Ma,  \n [wzma@must.edu. mo](wzma@must.edu. mo)  \n†These authors have contributed equally to this work  \nRECEIVED 06 September 2024  \nACCEPTED 23 April 2025  \nPUBLISHED 02 May 2025  \nCITATION  \nWang Z, Shi M, Liu B, Zhang X, Lin W, Yang Y, Huang Z, Yang D, Chu T, Zheng D and Ma W (2025) Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53 .  \nFront. Pharmacol. 16:1492305 .  \ndoi: 10.3389/fphar.2025.1492305  \nCOPYRIGHT  \n© 2025 Wang, Shi, Liu, Zhang, Lin, Yang, Huang, Yang, Chu, Zheng and Ma. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nLow-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53  \nZi Wang†, Meina Shi†, Beijia Liu, Xuening Zhang, Wanjun Lin, Yanchao Yang, Zifeng Huang, Dongfan Yang, Tong Chu, Dayuan Zheng and Wenzhe Ma*  \nFaculty of Chinese Medicine and State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China  \nBackground: Breast cancer’s high recurrence and treatment side effects demand safer, more effective therapies. Mutations in the critical TP53 gene, which normally prevents cancer, can instead promote it. This study explores if lowdose statins can curb mutant p53 activation in breast cancer’s immune signaling, hindering tumor immune evasion.  \nMethods: The study used diverse breast cancer cell lines with varying p53 statuses. Techniques included Western blot, transfection, qRT-PCR, coimmunoprecipitation, nuclear fractionation, and immunohistochemistry. In vivo experiments used BALB/c mice, with bioinformatics analysis via cBioPortal.  \nResults: The study found that suppressing mutant p53 restores innate immunity and enhances cancer treatment. Low-dose statins promoted IRF3 nuclear translocation by inhibiting mutant p53 . Lovastatin treatment in vivo increased phosphorylated TBK1 and IRF3 levels and induced CD8+ T lymphocyte inﬁltration in tumors.  \nConclusion: The ﬁndings suggest low-dose statins can enhance innate immunity in breast cancer by degrading mutant p53, offering new treatment possibilities. Caution is advised, and further research is needed to address limitations and provide solid evidence for clinical use.  \nKEYWORDS  \np53, statin, breast cancer, CGAS, STING  \n1 Introduction  \nIn 2020, breast cancer was diagnosed in 2.3 million women worldwide, with an annual growth rate of approximately 0.6%(Siegel et al., 2024) . By 2040, it is projected that there will be over three million new cases and more than one million deaths annually (Arnold et al., 2022) . The recurrence rate for breast cancer patients is as high as 10% annually, posing ongoing challenges, especially for those in the ﬁrst 2 years post-treatment (Colleoni et al., 2016). Breast cancer treatment includes chemotherapy, endocrine therapy, targeted therapy, and immunotherapies. Despite their effectiveness, these treatments often have signiﬁcant side effects (Ben-Baruch et al., 2015; Groner and Hynes, 2016; Kos et al., 2023; Robson et al., 2023) . Therefore, there is a pressing need for safer and more effective breast cancer  \nFrontiers in Pharmacology 01 [frontiersin.org](frontiersin.org)  \nWang et al. 10.3389/fphar.2025.1492305  \nGRAPHICAL ABSTRACT  \ntreatments. However, the development of new drugs involves mul","cbCaisDBF7R1P6Pw","https://ap.wps.com/l/cbCaisDBF7R1P6Pw","pdf",4556577,14,"English","# 1 Introduction\n# 2 Background and rationale\n# 3 Methods\n## 3.1 In vitro assays\n## 3.2 In vivo experiments\n# 4 Results\n# 5 Conclusion","[{\"question\":\"What problem does the study address in breast cancer therapy?\",\"answer\":\"It targets high recurrence and side effects by exploring a safer therapeutic strategy linked to mutant TP53–driven immune evasion.\"},{\"question\":\"How do the authors investigate the role of mutant p53 and low-dose statins?\",\"answer\":\"They use breast cancer cell lines with different p53 statuses and apply Western blot, transfection, qRT-PCR, co-immunoprecipitation, nuclear fractionation, and immunohistochemistry.\"},{\"question\":\"What key immune-related findings support the study’s conclusion?\",\"answer\":\"Statin treatment promotes IRF3 nuclear translocation; in vivo it increases phosphorylated TBK1 and IRF3 and induces CD8+ T lymphocyte infiltration in tumors.\"}]","Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53 - Original Research Article | PDF",1790145818,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8959005f55b9e376dc5ae4dabe5b81d3.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81f1ee8f301c073a88f640d4e662a4a8.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2831b84995194dd476fd24e92f0492a.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b9930a40876392a1ddf27e3cbaecc3c4.webp",980,1385]